NAD(P)H: Quinone oxidoreductase 1 activation reduces blood pressure through regulation of endothelial nitric oxide synthase acetylation in spontaneously hypertensive rats

American Journal of Hypertension

Volumn 28, Issue 1, 2015, Pages 50-57

  Kim, Yong Hoon ^a   Hwang, Jung Hwan ^a   Kim, Kyoung Shim ^a   Noh, Jung Ran ^a   Gang, Gil Tae ^a   Seo, Youngwon ^a   Nam, Ki Hoan ^a   Kwak, Tae Hwan ^b   Lee, Hee Gu ^a   Lee, Chul Ho ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b R and D Center KT and G Life Sciences Corp   (South Korea)

Author keywords

Blood pressure; ENOS; Hypertension; NQO1; SIRT1

Indexed keywords

NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SIRTUIN 1; ANTIHYPERTENSIVE AGENT; BETA-LAPACHONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME ACTIVATOR; ENZYME INHIBITOR; NAPHTHOQUINONE; NOS3 PROTEIN, MOUSE; NOS3 PROTEIN, RAT; NQO1 PROTEIN, MOUSE; NQO1 PROTEIN, RAT; SIRT1 PROTEIN, MOUSE; SIRT1 PROTEIN, RAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CELL CULTURE; CONTROLLED STUDY; DEACETYLATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOPRECIPITATION; IN VITRO STUDY; MOUSE; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; SPONTANEOUSLY HYPERTENSIVE RAT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; MALE; METABOLISM; PATHOPHYSIOLOGY; PROTEIN PROCESSING; TIME;

ACETYLATION; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CELL LINE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; HYPERTENSION; MALE; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS, INBRED SHR; SIRTUIN 1; TIME FACTORS;

EID: 84922356886     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu116     Document Type: Article

References (32)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endotheliumderived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84:9265-9269.
3. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 1989; 86:3375-3378.
4. Jamaluddin S, Liang Z, Lu JM, Yao Q, Chen C. Roles of cardiovascular risk factors in endothelial nitric oxide synthase regulation: an update. Curr Pharm Des 2013.
5. Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets 2012; 13:1207-1214.
6. Sessa WC. eNOS at a glance. J Cell Sci 2004; 117:2427-2429.
7. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2007; 104:14855-14860.
8. Chen Z, Peng IC, Cui X, Li YS, Chien S, Shyy JY. Shear stress, SIRT1, and vascular homeostasis. Proc Natl Acad Sci U S A 2010; 107:10268-10273.
9. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-196.
10. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106:1652-1658.
11. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18:864-870.
12. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P) H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000; 129:77-97.
13. Gaikwad A, Long DJ, 2nd, Stringer JL, Jaiswal AK. In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem 2001; 276:22559-22564.
14. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2:227-242.
15. Hwang JH, Kim DW, Jo EJ, Kim YK, Jo YS, Park JH, Yoo SK, Park MK, Kwak TH, Kho YL, Han J, Choi HS, Lee SH, Kim JM, Lee I, Kyung T, Jang C, Chung J, Kweon GR, Shong M. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes 2009; 58:965-974.
16. Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim HJ, Kim JY, Hwang JH, Tadi S, Yim YH, Lee KU, Park KG, Huh S, Min KN, Jeong KH, Park MG, Kwak TH, Kweon GR, Inukai K, Shong M, Lee IK. Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res 2009; 104:842-850.
17. Kim YH, Hwang JH, Noh JR, Gang GT, Kim do H, Son HY, Kwak TH, Shong M, Lee IK, Lee CH. Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovasc Res 2011; 91:519-527.
18. Kim YH, Hwang JH, Kim KS, Noh JR, Gang GT, Oh WK, Jeong KH, Kwak TH, Choi HS, Lee IK, Lee CH. Enhanced activation of NAD(P) H: quinone oxidoreductase 1 attenuates spontaneous hypertension by improvement of endothelial nitric oxide synthase coupling via tumor suppressor kinase liver kinase B1/adenosine 5'-monophosphate-activated protein kinase-mediated guanosine 5'-triphosphate cyclohydrolase 1 preservation. J Hypertens 2014; 32:306-317.
19. Kim YH, Hwang JH, Noh JR, Gang GT, Tadi S, Yim YH, Jeoung NH, Kwak TH, Lee SH, Kweon GR, Kim JM, Shong M, Lee IK, Lee CH. Prevention of salt-induced renal injury by activation of NAD(P) H:quinone oxidoreductase 1, associated with NADPH oxidase. Free Radic Biol Med 2012; 52:880-888.
20. Oh GS, Kim HJ, Choi JH, Shen A, Choe SK, Karna A, Lee SH, Jo HJ, Yang SH, Kwak TH, Lee CH, Park R, So HS. Pharmacological activation of NQO1 increases NAD levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int 2013; 85:547-560.
21. Gang GT, Hwang JH, Kim YH, Noh JR, Kim KS, Jeong JY, Choi DE, Lee KW, Jung JY, Shong M, Lee CH. Protection of NAD(P)H:quinone oxidoreductase 1 against renal ischemia/reperfusion injury in mice. Free Radic Biol Med 2013; 67C:139-149.
22. Gang GT, Kim YH, Noh JR, Kim KS, Jung JY, Shong M, Hwang JH, Lee CH. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity. Toxicol Lett 2013; 221:165-175.
23. Lazzarino G, Amorini AM, Fazzina G, Vagnozzi R, Signoretti S, Donzelli S, Di Stasio E, Giardina B, Tavazzi B. Single-sample preparation for simultaneous cellular redox and energy state determination. Anal Biochem 2003; 322:51-59.
24. Williamson DH, Lund P, Krebs HA. The redox state of free nicotinamide- adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J 1967; 103:514-527.
25. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, Starai VJ, Avalos JL, Escalante-Semerena JC, Grubmeyer C, Wolberger C, Boeke JD. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci U S A 2000; 97:6658-6663.
26. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013; 154:430-441.
27. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 1999; 399:601-605.
28. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001; 276:16587-16591.
29. Wang S, Xu J, Song P, Viollet B, Zou MH. In vivo activation of AMPactivated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 2009; 58:1893-1901.
30. Gradman AH. Strategies for combination therapy in hypertension. Curr Opin Nephrol Hypertens 2012; 21:486-491.
31. Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixeddose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin 2012; 28:1685-1697.
32. Kim YH, Hwang JH, Kim KS, Noh JR, Gang GT, Kim SW, Jang SP, Lee SJ, Her SH, Jeong KH, Kwak TH, Park WJ, Balyasnikova IV, Shong M, Lee CH. NQO1 activation regulates angiotensin-converting enzyme shedding in spontaneously hypertensive rats. Cardiovasc Res 2013; 99:743-750.